Sustainable Investment Analyst
Our Sustainable Investment Team takes an in-depth look at the companies likely to be most impacted by the drive to reduce the use of plastics.
The increasing resistance of bacteria to common antibiotics is one of the most important issues since modern medicine began, yet the wider costs and benefits are not fully understood.
Rising drug prices have been thrust into the limelight by the US presidential nomination campaigns. We look at the implications for the healthcare industry in light of this increased scrutiny.
Seema Suchak, ESG Analyst, explains Schroders’ new approach to reporting on sustainable investments.